
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
AAR2 (AAR2 Splicing Factor) encodes an RNA splicing factor involved in pre-mRNA processing. The protein participates in spliceosome function and regulation of mRNA maturation.
The U-87 MG cell line was derived from a malignant glioma of a female patient using an explant technique by J. Ponten and colleagues between 1966 and 1969. This human glioblastoma model has been extensively characterized and is reported to form malignant tumors consistent with glioblastoma in nude mice. U-87 MG is widely used in neuro-oncology research as an in vitro model for studying glioma biology, tumor growth mechanisms, cancer cell signaling, and evaluation of therapeutic strategies for malignant brain tumors.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 2
Reference Transcript: NM_015511
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use






Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?